Randomized trial of vitamin D versus placebo supplementation on markers of systemic inflammation in hypertensive patients.
Study Goal
The researchers aimed to investigate the effect of vitamin D supplementation on systemic markers of inflammation in hypertensive patients with low vitamin D levels.
Results Summary
The abstract does not provide specific results regarding the effects of vitamin D supplementation on inflammation markers or hypertension outcomes.
Population
200 hypertensive patients with 25-hydroxy-vitamin-D (25(OH)D) concentration below 30 ng/mL.
Effective Dosage
2800 IU of vitamin D (frequency not specified).
Duration
Not specified in the abstract.
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
vitamin D | neutral | inflammatory activity | Animal and cell models | - | modulates | #1 |
vitamin D supplementation | neutral | systemic markers of inflammation | hypertensive patients | - | investigate the effect | #2 |
BACKGROUND AND AIMS: Animal and cell models indicated that vitamin D modulates inflammatory activity, which is considered relevant in the pathogenesis of arterial hypertension and cardiovascular diseases. We therefore aimed to investigate the effect of vitamin D supplementation on systemic markers of inflammation in a cohort of hypertensive patients. METHODS AND RESULTS: The Styrian Vitamin D Hypertension Trial is a single-centre, double-blind, placebo-controlled study conducted from 2011 to 2014 in Austria. We enrolled 200 study participants with arterial hypertension and 25-hydroxy-vitamin-D (25(OH)D) concentration below 30 ng/mL. Study participants were randomized to receive either 2800 IU of vitamin D CONCLUSION: Vitamin D REGISTRATION: ClinicalTrials.gov Identifier: NCT02136771; EudraCT No. 2009-018,125-70. Start Date: 2011-04-06.